metronidazole based quadriple therapy — Competitive Intelligence Brief

metronidazole based quadriple therapy (metronidazole based quadriple therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy Helicobacter pylori DNA and bacterial cell integrity Gastroenterology / Infectious Disease Small molecule

Target snapshot

metronidazole based quadriple therapy (metronidazole based quadriple therapy) — mohamed bouchoucha. Metronidazole-based quadruple therapy combines metronidazole with three other agents (typically a proton pump inhibitor, bismuth compound, and tetracycline or clarithromycin) to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppressive mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metronidazole based quadriple therapy TARGET	metronidazole based quadriple therapy	mohamed bouchoucha	marketed	Antibiotic combination therapy	Helicobacter pylori DNA and bacterial cell integrity
Tetracycline, Metronidazole, Bismuth subcitrate	Tetracycline, Metronidazole, Bismuth subcitrate	Mackay Memorial Hospital	marketed	Antibiotic combination therapy	Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth)
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
Optimized bismuth quadruple therapy	Optimized bismuth quadruple therapy	Pontificia Universidad Catolica de Chile	marketed	Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen
Standard bismuth quadruple	Standard bismuth quadruple	Xijing Hospital of Digestive Diseases	marketed	Antibiotic combination therapy / Bismuth-based anti-ulcer agent	Helicobacter pylori (bacterial pathogen)
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy class)

1. West Virginia University · 2 drugs in this class
2. Mackay Memorial Hospital · 1 drug in this class
3. Takeda · 1 drug in this class
4. University of Valencia · 1 drug in this class
5. mohamed bouchoucha · 1 drug in this class